Tirzepatide
20mg
Tirzepatide activates GIP and GLP-1 receptors, producing compounding effects across appetite regulation, glucose metabolism, and fat mobilization. In Phase 3 trials, subjects lost an average 22% of body weight, with preferential visceral fat loss and preserved lean muscle.
Included free with every order
Bacteriostatic reconstitution solution and sterile dosing needles are included, a $30+ value, always included. Most suppliers charge extra. We never do.
Purity
99.3%
Form
Lyophilized powder
Storage
-20°C
Includes
Solution + needles
Research use only. Not for human consumption. Need help reconstituting? Use our dosing calculator.
Research Outcomes
What The Clinical Data Shows
Based on published peer-reviewed literature. Not medical claims.
22%
Average body weight reduction in Phase 3 trials
94%
Of subjects showed improved blood glucose markers
16 wks
Median time to first significant weight loss
Visceral fat loss. Imaging confirmed the majority of weight lost is visceral fat, with lean muscle largely preserved despite the scale of reduction.
Dual receptor mechanism. GIP activation triggers fat cell breakdown directly in adipose tissue, compounding with GLP-1-driven appetite suppression and glucose regulation.
Cardiovascular markers. Blood pressure, LDL, and triglycerides improved beyond what weight loss alone predicts; fasting insulin dropped up to 60% in some arms.
Sustained energy. Physical function and energy scores improved from week 8 onward, sustained through the full 72-week study period.
Research context. All findings are from peer-reviewed literature. Not FDA-approved. Sold for research purposes only. Results in research settings may vary. Not medical advice.